Viva Biotech Holdings Asset Resilience Ratio
Viva Biotech Holdings asset resilience ratio. Viva Biotech Holdings (VB0) has an Asset Resilience Ratio of 6.39% as of June 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Viva Biotech Holdings (VB0) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Viva Biotech Holdings (2017–2020)
Asset resilience ratio of Viva Biotech Holdings from 2017 to 2020. This chart shows how Viva Biotech Holdings's Asset Resilience Ratio has changed over time. Read Viva Biotech Holdings debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Viva Biotech Holdings's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Viva Biotech Holdings total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €504.93 Million | 6.39% |
| Total Liquid Assets | €504.93 Million | 6.39% |
Asset Resilience Insights
- Limited Liquidity: Viva Biotech Holdings maintains only 6.39% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Viva Biotech Holdings Industry Peers by Asset Resilience Ratio
Compare Viva Biotech Holdings's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
Viva Biotech Holdings Asset Resilience Ratio by Year (2017–2020)
Viva Biotech Holdings asset resilience ratio by year from 2017 to 2020. The table below shows the annual Asset Resilience Ratio data for Viva Biotech Holdings.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2020-12-31 | 0.61% | €49.50 Million ≈ $57.87 Million |
€8.15 Billion ≈ $9.53 Billion |
-0.95pp |
| 2019-12-31 | 1.56% | €29.63 Million ≈ $34.64 Million |
€1.90 Billion ≈ $2.22 Billion |
-0.17pp |
| 2017-12-31 | 1.73% | €3.50 Million ≈ $4.09 Million |
€202.40 Million ≈ $236.63 Million |
-- |
About Viva Biotech Holdings
Viva Biotech Holdings, an investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, including protein expression and purification, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacology and DMPK; chemistry services, such a… Read more